Mutation frequency in SCN-AML versus de novo AML
| Gene . | SCN . | Discovery . | ||||
|---|---|---|---|---|---|---|
| Mutation . | n . | Frequency, % . | Mutation . | n . | Frequency, % . | |
| FLT3 | 0 | 10 | 0.0 | 51 | 185 | 27.6 |
| KIT | 0† | 10 | 0.0 | 4 | 188 | 2.1 |
| CSF1R* | 0 | 9 | 0.0 | 0 | 94 | 0.0 |
| NRAS | 0 | 10 | 0.0 | 17 | 182 | 9.3 |
| KRAS | 0 | 10 | 0.0 | 3 | 187 | 1.6 |
| PTPN11 | 0 | 10 | 0.0 | 5 | 183 | 2.7 |
| JAK2 | 0 | 10 | 0.0 | 2 | 187 | 1.1 |
| NPM1 | 0 | 10 | 0.0 | 43 | 180 | 23.9 |
| RUNX1 | 0 | 10 | 0.0 | 9 | 182 | 4.9 |
| TP53 | 0 | 10 | 0.0 | 3 | 183 | 1.6 |
| SPI1 | 0 | 9 | 0.0 | 2 | 184 | 1.1 |
| CEBPA | 0 | 10 | 0.0 | 11 | 186 | 5.9 |
| ELA2 | 3 | 10 | 30.0 | 0 | 188 | 0.0 |
| CSF3R* | 3 | 10 | 30.0 | 0 | 91 | 0.0 |
| Gene . | SCN . | Discovery . | ||||
|---|---|---|---|---|---|---|
| Mutation . | n . | Frequency, % . | Mutation . | n . | Frequency, % . | |
| FLT3 | 0 | 10 | 0.0 | 51 | 185 | 27.6 |
| KIT | 0† | 10 | 0.0 | 4 | 188 | 2.1 |
| CSF1R* | 0 | 9 | 0.0 | 0 | 94 | 0.0 |
| NRAS | 0 | 10 | 0.0 | 17 | 182 | 9.3 |
| KRAS | 0 | 10 | 0.0 | 3 | 187 | 1.6 |
| PTPN11 | 0 | 10 | 0.0 | 5 | 183 | 2.7 |
| JAK2 | 0 | 10 | 0.0 | 2 | 187 | 1.1 |
| NPM1 | 0 | 10 | 0.0 | 43 | 180 | 23.9 |
| RUNX1 | 0 | 10 | 0.0 | 9 | 182 | 4.9 |
| TP53 | 0 | 10 | 0.0 | 3 | 183 | 1.6 |
| SPI1 | 0 | 9 | 0.0 | 2 | 184 | 1.1 |
| CEBPA | 0 | 10 | 0.0 | 11 | 186 | 5.9 |
| ELA2 | 3 | 10 | 30.0 | 0 | 188 | 0.0 |
| CSF3R* | 3 | 10 | 30.0 | 0 | 91 | 0.0 |
Only those SCN samples with AML were included. The Discovery and CALBG de novo AML data sets were combined. Germ line nonsynonymous mutations and samples with inadequate sequence coverage were excluded.
Not sequenced in the CALBG samples.
The T801I KIT SNP was excluded because it has been shown to be a nonactivating mutation.